MANAGEMENT OF INHIBITORS IN HEMOPHILIA
Introduction: The improved understanding of Acute Myeloid Leukemia (AML) pathobiology has led to significant advances in treatment options. AML is a highly heterogeneous disease, with clinical, morphological, cytogenetic, and molecular variability, which is crucial for developing targeted therapies...
Saved in:
| Main Author: | Gaye Kalacı Katayıfçı |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | Hematology, Transfusion and Cell Therapy |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2531137924029535 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INTERVENTIONAL PROCEDURE IN HEMOPHILIA A PATIENT WITH EXTENDED HALF-LIFE FACTOR THERAPY- CIRCUMCISION- CASE REPORT
by: Ferda Can, et al.
Published: (2024-12-01) -
MOLECULAR MECHANISMS OF INHIBITOR DEVELOPMENT IN HEMOPHILIA
by: Davide Matino, et al.
Published: (2020-01-01) -
HLA variants and inhibitor development in hemophilia A: results from the HEMFIL study group
by: Márcio Antônio Portugal Santana, et al.
Published: (2024-12-01) -
HEMOPHILIA: ADVANCES IN TREATMENTS
by: Nurgül Karakaya
Published: (2024-12-01) -
Gene therapy for hemophilia
by: Peter J. Lenting, et al.
Published: (2024-12-01)